SCHEMBL7922595

SCHEMBL7922595

COC(=O)Cc1nc(-c2ccncc2)oc1C

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
HSD17B10 Q99714 2/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
PPARG P37231 3/20 0.43
PPARA Q07869 2/20 0.43
PPARD Q03181 1/20 0.43
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
TP53 P04637 2/20 0.42
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL821081 0.87 KDM4E (0.57) KDM4EHSD17B10ALDH1A1MAPTTSHR
SCHEMBL2930640 0.87 KDM4E (0.74) KDM4EMAPTLMNAHPGDSMN1; SMN2
SCHEMBL7906307 0.86 KDM4E (0.56) KDM4EHSD17B10ALDH1A1MAPTGAA
SCHEMBL4893515 0.85 KDM4E (0.70) KDM4EMAPTLMNAHPGDSMN1; SMN2
SCHEMBL6505735 0.85 KDM4E (0.55) KDM4EHSD17B10ALDH1A1MAPTGAA
SCHEMBL6607518 0.85 LMNA (0.60) KDM4EHSD17B10ALDH1A1MAPTGAA
SCHEMBL5215068 0.85 TARBP2 (0.55) KDM4EHSD17B10ALDH1A1MAPTGAA
SCHEMBL10652783 0.85 HSD17B10 (0.61) KDM4EHSD17B10ALDH1A1MAPTTSHR
SCHEMBL6606155 0.84 PPARA (0.52) KDM4EMAPTPPARGPPARAPPARD
SCHEMBL6293021 0.83 KDM4E (0.52) KDM4EHSD17B10ALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed